Healthcare / Medical DevicesXETRA
$16.19
+0.32 (+1.98%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $32.4M · quality 70.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
58/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.0B
P/E
20.5x
↑EV/EBITDA
9.9x
↓ROE
19.4%
↑Gross Margin
49.0%
↑Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.0%
FCF CAGR
+65.0%
FCF margin
10.4%
FCF / Net income
0.66x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $312.0M · net income $48.8M · FCF $32.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $312.0M | $312.0M | $295.9M | $246.1M | $222.2M |
| Net Income | $48.8M | $48.8M | $33.3M | $26.3M | $29.3M |
| EBITDA | $94.3M | $94.3M | $81.0M | $59.7M | $57.9M |
| EPS | 0.78 | 0.78 | 0.53 | 0.42 | 0.47 |
| Gross Margin | 49.0% | 49.0% | 48.4% | 46.1% | 48.0% |
| Operating Margin | 24.1% | 24.1% | 22.7% | 18.9% | 20.7% |
| Net Margin | 15.6% | 15.6% | 11.2% | 10.7% | 13.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.25 | 0.25 | 0.23 |
| Current Ratio | 3.41 | 3.41 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $32.4M | $32.4M | $49.4M | $21.1M | $7.2M |
| Returns | |||||
| ROE | 19.4% | 19.4% | 14.9% | 11.8% | 13.8% |
| Valuation | |||||
| P/E | 20.49 | 20.49 | 30.42 | 29.00 | 29.00 |
| EV/EBITDA | 9.89 | 9.89 | 11.71 | 12.56 | 14.12 |
| P/B | 4.04 | 4.04 | 4.52 | 3.43 | 4.01 |
| Growth & Yield | |||||
| Revenue Growth | 5.4% | 5.4% | 20.2% | 10.7% | — |
| EPS Growth | 47.2% | 47.2% | 26.2% | -10.6% | — |
| Dividend Yield | 1.3% | 1.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
22.6%
EPS terminal req.
$1.44
Spread vs growth
24.6%
5Y implied EPS CAGR
17.4%
EPS terminal req.
$1.74
Spread vs growth
29.8%
10Y implied EPS CAGR
13.6%
EPS terminal req.
$2.80
Spread vs growth
33.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.0%
Start / end P/E
39.1x → 21.2x
EPS bridge
0.53 → 0.78
Residual
-21.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.